Pfizer Inc.
PFENYSE
$30.28
Last price · USD
- Market cap
- $172.2B
- P/E
- 22.3x
- EV / EBITDA
- 14.2x
- P/S
- 2.8x
- FCF yield
- 5.3%
- Div. yield
- 5.68%
Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.
Revenue
$62.58B
-1.6%
4Y CAGR -6.3%
Gross profit
$44.01B
+5.2%
4Y CAGR -1.6%
Operating income
$15.44B
-6.3%
4Y CAGR -7.2%
Net income
$7.77B
-3.1%
4Y CAGR -23.0%
EPS (diluted)
$1.36
-3.5%
4Y CAGR -23.1%
Free cash flow
$9.08B
-7.7%
4Y CAGR -25.8%
Revenue & net income
Fiscal 2021–2025 · USD
RevenueNet income
Valuation
At $30.28 · FY2025 fundamentals
- Market cap
- $172.2B
- Enterprise value
- $238.4B
- P/E
- 22.3x
- P/S
- 2.8x
- P/B
- 2.0x
- EV / EBITDA
- 14.2x
- EV / Sales
- 3.8x
- Earnings yield
- 4.5%
- FCF yield
- 5.3%
- Shareholder yield
- 5.7%
Profitability
Margins as a share of revenue
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Gross margin | 70.3%+12.7pp | 57.7% | |
| Operating margin | 24.7%-0.9pp | 25.6% | |
| EBITDA margin | 26.8%-11.1pp | 37.9% | |
| Net margin | 12.4%-14.8pp | 27.2% | |
| FCF margin | 14.5%-22.2pp | 36.7% |
Returns & financial health
FY2025 with 4-year trend
| Metric | Latest | 4Y ago | Trend |
|---|---|---|---|
| Return on equity | 9.0% | 28.7% | |
| Return on invested capital | 10.1% | 17.1% | |
| Return on assets | 3.7% | 12.2% | |
| Debt / equity | 0.78x | 0.48x | |
| Net debt / EBITDA | 3.95x | 1.14x | |
| Current ratio | 1.16x | 1.40x |
Cash & equivalents
$1.14B
Total debt
$67.42B
Capital allocation
How PFE used its cash in FY2025
- Operating cash flow
- $11.71B
- Capital expenditure
- $2.63B
- Dividends paid
- $9.77B
- Share repurchases
- $0.00
- Stock-based compensation
- $799M
- Diluted shares
- 5.69B
- Share count change (4Y)
- -0.4%
Analyst estimates
Consensus for upcoming fiscal years
| Fiscal year | Revenue | Growth | EPS | Growth |
|---|---|---|---|---|
| FY2025 actual | $62.58B | $1.36 | ||
| FY2026E14 analysts | $62.25B | -0.5% | $2.96 | +117.3% |
| FY2027E13 analysts | $59.82B | -3.9% | $2.89 | -2.1% |
| FY2028E8 analysts | $54.74B | -8.5% | $2.48 | -14.3% |
About Pfizer Inc.
Healthcare · Drug Manufacturers - General
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis.
pfizer.com- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla
- Employees
- 75,000
- Headquarters
- New York City, NY, US
- IPO date
- 1972-06-01
Pfizer Inc. (PFE) — frequently asked questions
Answered from the company's SEC filings
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide.
Explore the full income statement, balance sheet and cash flow statement. Not investment advice.